Your browser is no longer supported. Please, upgrade your browser.
Settings
BTX BioTime, Inc. daily Stock Chart
BTX [NYSE]
BioTime, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own5.30% Shs Outstand131.72M Perf Week-10.49%
Market Cap168.60M Forward P/E- EPS next Y-0.28 Insider Trans0.02% Shs Float118.75M Perf Month-15.11%
Income-73.00M PEG- EPS next Q-0.07 Inst Own44.00% Short Float12.30% Perf Quarter-25.58%
Sales5.20M P/S32.42 EPS this Y-151.70% Inst Trans0.72% Short Ratio24.63 Perf Half Y-26.23%
Book/sh1.35 P/B0.95 EPS next Y-250.00% ROA-51.00% Target Price6.75 Perf Year-30.48%
Cash/sh0.16 P/C7.84 EPS next 5Y- ROE-54.60% 52W Range1.17 - 2.39 Perf YTD-21.42%
Dividend- P/FCF- EPS past 5Y16.70% ROI18.30% 52W High-44.76% Beta2.21
Dividend %- Quick Ratio8.20 Sales past 5Y-2.50% Gross Margin94.20% 52W Low13.34% ATR0.12
Employees92 Current Ratio8.20 Sales Q/Q-41.20% Oper. Margin- RSI (14)45.26 Volatility10.41% 8.79%
OptionableYes Debt/Eq0.01 EPS Q/Q323.10% Profit Margin- Rel Volume0.53 Prev Close1.28
ShortableYes LT Debt/Eq0.01 EarningsNov 08 BMO Payout- Avg Volume592.96K Price1.32
Recom1.80 SMA20-1.10% SMA50-10.27% SMA200-23.64% Volume186,426 Change3.32%
Dec-11-18Initiated Oppenheimer Outperform $3.50
Feb-02-18Initiated Lake Street Buy $8
Mar-31-17Initiated Raymond James Outperform $6
Sep-23-16Initiated Ladenburg Thalmann Buy
Feb-19-16Initiated Chardan Capital Markets Buy $5
Dec-22-15Initiated Oppenheimer Outperform $10
Dec-19-11Upgrade WBB Securities Buy → Strong Buy $8
Nov-16-11Upgrade WBB Securities Speculative Buy → Buy $6 → $8
Aug-11-11Initiated WBB Securities Speculative Buy $6
Jan-06-11Initiated BioLogic Equity Research Sell $2
Dec-04-18 08:00AM  BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke Business Wire
Dec-03-18 07:55AM  New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Nov-29-18 08:00AM  BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018 Business Wire +20.36%
08:00AM  AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference Business Wire
07:00AM  AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American Business Wire
Nov-28-18 08:00AM  BioTime Announces Distribution of AgeX Therapeutics Shares Business Wire
Nov-09-18 04:10PM  Asterias Biotherapeutics Reports Third Quarter Results GlobeNewswire
Nov-08-18 11:35PM  Edited Transcript of BTX earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents -5.24%
01:49PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Asterias Biotherapeutics, Inc. (AST) on Behalf of Stockholders and Encourages AST Investors to Contact the Firm GlobeNewswire
07:53AM  What Kind Of Shareholder Owns Most BioTime Inc (NYSEMKT:BTX) Stock? Simply Wall St.
07:11AM  BioTime: 3Q Earnings Snapshot Associated Press
06:35AM  BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company Business Wire
06:30AM  BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update Business Wire
Nov-06-18 04:30PM  BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call Business Wire
Nov-05-18 08:00AM  BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd. Business Wire
Nov-01-18 11:28AM  Earnings Preview: BioTime (BTX) Q3 Earnings Expected to Decline Zacks +6.67%
Oct-30-18 08:00AM  BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018 Business Wire
Oct-29-18 08:00AM  BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting Business Wire -6.57%
Oct-25-18 08:00AM  BioTime Announces November 16, 2018 Record Date and November 28, 2018 Distribution Date for the Distribution of Age-X Therapeutics Shares Business Wire
Oct-23-18 07:45AM  Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure N.V, Catalent, Apple, BioTime, and PDL BioPharma New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-22-18 08:00AM  BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th Business Wire
Sep-27-18 07:00AM  BioTime to Present at the Upcoming Ladenburg Thalmann and MicroCap Conferences Business Wire
Sep-25-18 07:00AM  BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies Business Wire
Sep-21-18 07:00AM  BioTime Warrants to Expire on October 1, 2018 Business Wire +6.05%
Sep-18-18 07:00AM  BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer Business Wire
Sep-17-18 01:00AM  BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders Business Wire
Sep-04-18 09:37AM  Can The Uptrend Continue for BioTime (BTX)? Zacks
06:55AM  BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence Business Wire
Aug-28-18 07:00AM  BioTimes CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences Business Wire
Aug-23-18 08:25AM  Research Report Identifies Cloudera, Snap, Social Reality, BioTime, Renewable Energy Group, and Mattel with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-16-18 08:00AM  AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance Business Wire
07:00AM  BioTime to Present Data at the Military Health System Research Symposium Business Wire
Aug-03-18 11:24PM  Edited Transcript of BTX earnings conference call or presentation 2-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 06:35PM  BioTime (BTX) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:31PM  BioTime: 2Q Earnings Snapshot Associated Press
04:05PM  BioTime Reports Second Quarter Results and Recent Corporate Accomplishments Business Wire
02:30PM  BioTime, Inc. to Host Earnings Call ACCESSWIRE
08:00AM  BioTime to Receive $43 Million From Juvenescence Business Wire
07:00AM  BioTime Announces the Start of an Investigator Initiated Study of Premvia Designed and Conducted by Dr. Gordon H. Sasaki Business Wire
Aug-01-18 06:12PM  BioTime Announces Distribution Ratio for Distribution of AgeX Therapeutics Shares Business Wire -7.31%
Jul-25-18 07:00AM  Data from BioTimes OpRegen® Program to Be Presented at AAO 2018 Business Wire
Jul-23-18 04:12PM  Here's Why BioTime, Inc Rose as Much as 14.3% Today Motley Fool +11.39%
07:00AM  BioTime to Announce Second Quarter 2018 Results on August 2, 2018 Business Wire
Jul-12-18 09:04AM  BioTime (BTX) in Focus: Stock Moves 7.3% Higher Zacks
Jul-11-18 07:00AM  AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, July 12 in New York City Business Wire +7.27%
Jul-10-18 07:00AM  BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Therapeutics Shares Business Wire
Jun-29-18 07:00AM  BioTime Awarded Grant From the NIH Business Wire
Jun-26-18 04:37AM  Should You Expect Forbuild SA (WSE:BTX) To Continue Delivering An ROE Of 10.89%? Simply Wall St.
Jun-25-18 07:00AM  BioTime Licenses GMP Cell Line to Goliver Therapeutics Business Wire -5.96%
Jun-19-18 07:00AM  Free Technical Research on BioPharmX and Three More Biotech Equities bio ACCESSWIRE
Jun-14-18 11:37AM  June Fundamental Stock Pick: Forbuild SA (WSE:BTX) Simply Wall St.
08:15AM  Detailed Research: Economic Perspectives on Verizon Communications, PayPal, Menlo Therapeutics, iClick Interactive Asia Group, BioTime, and Adobe What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jun-11-18 07:00AM  AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence Business Wire
Jun-08-18 07:00AM  BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares Business Wire
Jun-05-18 07:00AM  AgeX Therapeutics Appoints John F. Mauldin to Board of Directors Business Wire +5.06%
May-30-18 07:00AM  BioTime to Present at the 8th Annual LD Micro Invitational Business Wire
May-29-18 07:00AM  BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD Business Wire
May-24-18 07:00AM  BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites Business Wire
May-22-18 04:15AM  How Does Forbuild SAs (WSE:BTX) Earnings Growth Stack Up Against Industry Performance? Simply Wall St.
May-17-18 07:00AM  AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London Business Wire
May-16-18 09:53PM  Edited Transcript of BTX earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 05:23PM  BioTime: 1Q Earnings Snapshot Associated Press
04:05PM  BioTime Reports First Quarter Results and Recent Corporate Accomplishments Business Wire
11:47AM  BioTime Inc (NYSEMKT:BTX): Earnings Expected To Remain Subdued Simply Wall St.
May-02-18 07:00AM  AgeX Announces NIH Grant Award Business Wire
May-01-18 11:02AM  With An ROE Of 9.05%, Has Forbuild SAs (WSE:BTX) Management Done Well? Simply Wall St.
08:00AM  BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO Business Wire
Apr-26-18 07:00AM  BioTime to Announce First Quarter 2018 Results on May 10, 2018 Business Wire
Apr-16-18 07:00AM  Data from BioTimes OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018 Business Wire
Apr-10-18 07:41AM  BioTime (BTX): Moving Average Crossover Alert Zacks +5.06%
Apr-09-18 08:00AM  Data from BioTimes OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit Business Wire
Mar-27-18 07:00AM  BioTime Announces Cash Sale of Ascendance Biotechnology Business Wire
Mar-21-18 07:40AM  Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin ACCESSWIRE
Mar-16-18 01:20PM  Edited Transcript of BTX earnings conference call or presentation 15-Mar-18 8:30pm GMT Thomson Reuters StreetEvents +9.84%
Mar-15-18 05:35PM  BioTime reports 4Q loss Associated Press -8.30%
04:05PM  BioTime Reports Fourth Quarter and Fiscal 2017 Results Business Wire
12:00PM  BioTime, Inc. to Host Earnings Call ACCESSWIRE
10:44AM  BioTime Q4 Earnings Outlook Benzinga
Mar-14-18 08:38AM  BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session Zacks
08:10AM  Research Report Identifies Supernus Pharmaceuticals, Celestica, Global Blood Therapeutics, BioTime, CyberArk Software, and Tivity Health, Inc. with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-13-18 08:00AM  BioTime Submits CE Mark Application for European Approval of Renevia® Business Wire +5.99%
Mar-07-18 08:00AM  BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial Business Wire
Mar-05-18 08:00AM  BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018 Business Wire
Mar-01-18 08:00AM  AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018 Business Wire
Feb-28-18 08:00AM  BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference Business Wire
Feb-26-18 07:00AM  BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs Business Wire
Feb-22-18 07:00AM  BioTime Appoints Cavan Redmond to Its Board of Directors Business Wire
Feb-15-18 07:00AM  Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018 Business Wire
Feb-07-18 07:00AM  BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018 Business Wire
Jan-29-18 07:00AM  Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference Business Wire +7.27%
Jan-23-18 07:00AM  BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018 Business Wire
Jan-22-18 07:00AM  BioTime Announces Clinical and Corporate Milestone Targets for 2018 Business Wire
Jan-18-18 07:00AM  AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on Stem Cell Innovations That Will Change the World Business Wire
Jan-17-18 07:00AM  BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate Business Wire
Jan-05-18 04:30PM  AgeX Therapeutics to Present at Biotech Showcase Annual Conference Business Wire
Jan-02-18 07:00AM  AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer Business Wire +6.51%
Dec-29-17 11:38AM  ETFs with exposure to BioTime, Inc. : December 29, 2017 Capital Cube
Dec-20-17 07:49AM  Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys Zacks
07:00AM  BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 10, 2018 Business Wire
Dec-19-17 06:23AM  Try Rising P/E Investing With 5 Top-Ranked Stocks Zacks
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patton Stephana EileneGeneral Counsel & SecretaryOct 04Option Exercise0.0013,750021,250Oct 09 06:19 PM
SKIBSTED RUSSELLChief Financial OfficerOct 04Option Exercise0.0011,250013,250Oct 09 07:18 PM
WEST MICHAEL DCo-Chief Executive OfficerSep 17Option Exercise0.0010,9380897,696Sep 19 09:38 PM
ANDREWS DEBORAH JDirectorSep 11Buy2.351,6043,76910,000Sep 13 04:17 PM
WEST MICHAEL DCo-Chief Executive OfficerJul 10Option Exercise0.001,5620887,299Jul 12 07:50 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerJul 10Option Exercise0.004,6870103,005Jul 12 07:45 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerApr 10Option Exercise0.004,688099,940Apr 12 08:39 PM
WEST MICHAEL DCo-Chief Executive OfficerApr 10Option Exercise0.001,5630886,278Apr 12 09:00 PM
WEST MICHAEL DCo-Chief Executive OfficerJan 10Option Exercise0.001,5620885,401Jan 12 08:30 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerJan 10Option Exercise0.004,687097,309Jan 12 09:17 PM